264 related articles for article (PubMed ID: 36982792)
41. Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity.
Aputen AD; Elias MG; Gilbert J; Sakoff JA; Gordon CP; Scott KF; Aldrich-Wright JR
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396859
[TBL] [Abstract][Full Text] [Related]
42. Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.
Wang Y; Luo Z; Zhou D; Wang X; Chen J; Gong S; Yu Z
Biomater Sci; 2021 Jun; 9(11):4110-4119. PubMed ID: 33949442
[TBL] [Abstract][Full Text] [Related]
43. Bis- and Tetrakis(carboxylato)platinum(IV) complexes with mixed axial ligands - synthesis, characterization, and cytotoxicity.
Hoffmeister BR; Hejl M; Adib-Razavi MS; Jakupec MA; Galanski M; Keppler BK
Chem Biodivers; 2015 Apr; 12(4):559-74. PubMed ID: 25879501
[TBL] [Abstract][Full Text] [Related]
44. Structure-Guided Design of Ferritin-Platinum Prodrugs for Targeted Therapy of Esophageal Squamous Cell Carcinoma.
Jiang B; Chen X; Wang S; Wang S; Ma S; Lu Y; Ma L; Liang Q; Xiao H; Zhang L; Yan X; Fan K
ACS Nano; 2024 Apr; 18(17):11217-11233. PubMed ID: 38627234
[TBL] [Abstract][Full Text] [Related]
45. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.
Kelland LR; Murrer BA; Abel G; Giandomenico CM; Mistry P; Harrap KR
Cancer Res; 1992 Feb; 52(4):822-8. PubMed ID: 1737343
[TBL] [Abstract][Full Text] [Related]
46. Abplatin
Li X; Zhang L; Li T; Li S; Wu W; Zhao L; Xie P; Yang J; Li P; Zhang Y; Xiao H; Yu Y; Zhao Z
J Nanobiotechnology; 2022 Jun; 20(1):258. PubMed ID: 35659243
[TBL] [Abstract][Full Text] [Related]
47. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
48. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
49. Visible light-activatable platinum(IV) prodrugs harnessing CD36 for ovarian cancer therapy.
Jayawardhana AMDS; Bhandari S; Kaspi-Kaneti AW; Kshetri M; Qiu Z; Cheline M; Shen H; Dunietz BD; Zheng YR
Dalton Trans; 2023 Aug; 52(31):10942-10950. PubMed ID: 37490033
[TBL] [Abstract][Full Text] [Related]
50. Antiproliferative activity of a series of cisplatin-based Pt(IV)-acetylamido/carboxylato prodrugs.
Ravera M; Gabano E; Zanellato I; Fregonese F; Pelosi G; Platts JA; Osella D
Dalton Trans; 2016 Mar; 45(12):5300-9. PubMed ID: 26903367
[TBL] [Abstract][Full Text] [Related]
51. An upconversion nanoplatform for simultaneous photodynamic therapy and Pt chemotherapy to combat cisplatin resistance.
Ai F; Sun T; Xu Z; Wang Z; Kong W; To MW; Wang F; Zhu G
Dalton Trans; 2016 Aug; 45(33):13052-60. PubMed ID: 27430044
[TBL] [Abstract][Full Text] [Related]
52. Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activity.
Pichler V; Heffeter P; Valiahdi SM; Kowol CR; Egger A; Berger W; Jakupec MA; Galanski MS; Keppler BK
J Med Chem; 2012 Dec; 55(24):11052-61. PubMed ID: 23194425
[TBL] [Abstract][Full Text] [Related]
53. BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity.
Yao H; Chen S; Deng Z; Tse MK; Matsuda Y; Zhu G
Inorg Chem; 2020 Aug; 59(16):11823-11833. PubMed ID: 32799491
[TBL] [Abstract][Full Text] [Related]
54. Imidazole modified Pt(iv) prodrug-loaded multi-stage pH responsive nanoparticles to overcome cisplatin resistance.
Kang X; Wang Y; Chen Z; Wu Y; Chen H; Yang X; Yu C
Chem Commun (Camb); 2020 Sep; 56(76):11271-11274. PubMed ID: 32830841
[TBL] [Abstract][Full Text] [Related]
55. Effective platinum(IV) prodrugs conjugated with lonidamine as a functional group working on the mitochondria.
Chen H; Chen F; Hu W; Gou S
J Inorg Biochem; 2018 Mar; 180():119-128. PubMed ID: 29253663
[TBL] [Abstract][Full Text] [Related]
56. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O.
Ali MS; Khan SR; Ojima H; Guzman IY; Whitmire KH; Siddik ZH; Khokhar AR
J Inorg Biochem; 2005 Mar; 99(3):795-804. PubMed ID: 15708801
[TBL] [Abstract][Full Text] [Related]
57. A Novel Platinum-based Compound with Preferential Cytotoxic Activity against a Panel of Cancer Cell Lines.
Shahsavar F; Bozorgmehr M; Mirzadegan E; Abedi A; Lighvan ZM; Mohammadi F; Safari N; Amani V; Zarnani AH
Anticancer Agents Med Chem; 2016; 16(3):393-403. PubMed ID: 26899296
[TBL] [Abstract][Full Text] [Related]
58. Platinum(II) complexes with l-methionylglycine and l-methionyl-l-leucine ligands: synthesis, characterization and in vitro antitumoral activity.
Kaluderović GN; Schmidt H; Paschke R; Kalinowski B; Dietrich A; Mueller T; Steinborn D
J Inorg Biochem; 2007 Mar; 101(3):543-9. PubMed ID: 17223197
[TBL] [Abstract][Full Text] [Related]
59. New platinum(II) and palladium(II) complexes with substituted terpyridine ligands: synthesis and characterization, cytotoxicity and reactivity towards biomolecules.
Savić A; Marzo T; Scaletti F; Massai L; Bartoli G; Hoogenboom R; Messori L; Van Deun R; Van Hecke K
Biometals; 2019 Feb; 32(1):33-47. PubMed ID: 30367340
[TBL] [Abstract][Full Text] [Related]
60.
Lee VEY; Lim ZC; Chew SL; Ang WH
Inorg Chem; 2021 Feb; 60(3):1823-1831. PubMed ID: 33464875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
